Skip Navigation

Publication Detail

Title: Regulation of renal calbindin expression during cisplatin-induced kidney injury.

Authors: George, Blessy; Szilagyi, John T; Joy, Melanie S; Aleksunes, Lauren M

Published In J Biochem Mol Toxicol, (2022 Jul)

Abstract: Since the discovery of calbindin release into the urine during renal injury, there has been growing interest in the utility of this protein as a biomarker of nephrotoxicity. However, little is known about the intrarenal regulation of the release and expression of this calcium-regulating protein during kidney injury. We sought to characterize the time-dependent expression and excretion of the protein calbindin in the distal tubule in comparison to kidney injury molecule-1 (Kim-1), a protein in the proximal tubule, in mice treated with cisplatin. Urine, blood, and kidneys were collected from male C57BL/6 mice treated with vehicle or cisplatin (20 mg/kg ip). Urinary concentrations of calbindin and Kim-1 were elevated by 11.6-fold and 2.5-fold, respectively, within 2 days after cisplatin. Circulating creatinine and blood urea nitrogen levels increased in cisplatin-treated mice by 3 days, confirming the development of acute kidney injury. Time-dependent decreases in intrarenal calbindin protein were observed on Days 3 and 4 and a 200-fold upregulation of calbindin (CALB1) and KIM-1 messenger RNAs (mRNAs) was observed on Day 3. These data suggest that early loss of calbindin protein into the urine along with declines in renal calbindin levels initiates a compensatory induction of mRNA expression at later time points (Days 3 and 4). Understanding the regulation of calbindin during cisplatin nephrotoxicity further enhances its utility as a potential urinary biomarker of kidney damage. The results of the current study support the combined use of a proximal (Kim-1) and distal tubule (calbindin) marker to phenotype acute kidney injury secondary to cisplatin administration.

PubMed ID: 35403300 Exiting the NIEHS site

MeSH Terms: Acute Kidney Injury*/chemically induced; Acute Kidney Injury*/metabolism; Animals; Antineoplastic Agents*/adverse effects; Biomarkers/metabolism; Calbindins/metabolism; Cisplatin/toxicity; Kidney/metabolism; Male; Mice; Mice, Inbred C57BL

Back
to Top